Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19

Thomas D. Norton, Mazhar Thakur, Samit Ganguly, Shazia Ali, Jesse Chao, Alpana Waldron, Jing Xiao, Kenneth C. Turner, John D. Davis, Susan C. Irvin, Cynthia Pan, Dominique Atmodjo, Andrea T. Hooper, Jennifer D. Hamilton, Mohamed Hussein, Danise Subramaniam, Lilia Roque-Guerrero, Anita Kohli, Eleftherios Mylonakis, Gregory P. GebaEdward Cox, Ned Braunstein, Paula Dakin, Bari Kowal, Rafia Bhore, A. Thomas DiCioccio, Diana Hughes, Gary A. Herman

Research output: Contribution to journalArticlepeer-review

Abstract

The safety of casirivimab + imdevimab (CAS + IMD) (anti-severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] monoclonal antibodies [mAbs]) in pediatric outpatients with coronavirus disease 2019 (COVID-19) was evaluated in a randomized phase 1/2/3 trial. Consistent with adults, CAS + IMD was generally well tolerated with low drug-induced immunogenicity rates. The findings support the development of next-generation anti-SARS-CoV-2 mAbs for at-risk pediatric patients.

Original languageEnglish (US)
Pages (from-to)589-593
Number of pages5
JournalJournal of the Pediatric Infectious Diseases Society
Volume13
Issue number11
DOIs
StatePublished - Nov 1 2024

Keywords

  • COVID-19
  • monoclonal antibodies
  • outpatients
  • pediatrics
  • treatment

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19'. Together they form a unique fingerprint.

Cite this